Trent J - Search Results

1

Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.

George S, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Razak AA, Gordon MS, Somaiah N, Jennings J, Meade J, Shi K, Su Y, Ruiz-Soto R, Janku F. George S, et al. Among authors: trent j. Eur J Cancer. 2021 Sep;155:236-244. doi: 10.1016/j.ejca.2021.07.010. Epub 2021 Aug 12. Eur J Cancer. 2021. PMID: 34391056 Free PMC article.

2

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.

Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS. Patel SR, et al. Among authors: trent j. Cancer. 2003 Jun 1;97(11):2848-52. doi: 10.1002/cncr.11385. Cancer. 2003. PMID: 12767099 Free article. Clinical Trial.

3

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. Trent JC, et al. Cancer. 2003 Dec 15;98(12):2693-9. doi: 10.1002/cncr.11875. Cancer. 2003. PMID: 14669291 Free article. Clinical Trial.

4

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. Chen LL, et al. Among authors: trent jc. Cancer Res. 2004 Sep 1;64(17):5913-9. doi: 10.1158/0008-5472.CAN-04-0085. Cancer Res. 2004. PMID: 15342366

5

Update on the biology and therapy of gastrointestinal stromal tumors.

D'Amato G, Steinert DM, McAuliffe JC, Trent JC. D'Amato G, et al. Cancer Control. 2005 Jan-Feb;12(1):44-56. doi: 10.1177/107327480501200106. Cancer Control. 2005. PMID: 15668652 Free article. Review.

6

Imatinib mesylate in the treatment of gastrointestinal stromal tumour.

Steinert DM, McAuliffe JC, Trent JC. Steinert DM, et al. Expert Opin Pharmacother. 2005 Jan;6(1):105-13. doi: 10.1517/14656566.6.1.105. Expert Opin Pharmacother. 2005. PMID: 15709888 Review.

7

Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.

Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Steinert DM, et al. Cancer. 2006 Apr 1;106(7):1617-23. doi: 10.1002/cncr.21781. Cancer. 2006. PMID: 16518826 Free article.

8

New developments in gastrointestinal stromal tumor.

Trent JC, Benjamin RS. Trent JC, et al. Curr Opin Oncol. 2006 Jul;18(4):386-95. doi: 10.1097/01.cco.0000228747.02660.e2. Curr Opin Oncol. 2006. PMID: 16721136 Review.

9

Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.

Trent JC, Ramdas L, Dupart J, Hunt K, Macapinlac H, Taylor E, Hu L, Salvado A, Abbruzzese JL, Pollock R, Benjamin RS, Zhang W. Trent JC, et al. Cancer. 2006 Oct 15;107(8):1898-908. doi: 10.1002/cncr.22214. Cancer. 2006. PMID: 16986125 Free article.

10

Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.

Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK. Chirieac LR, et al. Among authors: trent jc. Cancer. 2006 Nov 1;107(9):2237-44. doi: 10.1002/cncr.22226. Cancer. 2006. PMID: 16998931 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

966 results

Search Page